31,939 Shares in Supernus Pharmaceuticals, Inc. $SUPN Acquired by Westover Capital Advisors LLC

Westover Capital Advisors LLC purchased a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 31,939 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,587,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Royal Bank of Canada boosted its stake in Supernus Pharmaceuticals by 68.1% during the 1st quarter. Royal Bank of Canada now owns 11,669 shares of the specialty pharmaceutical company’s stock valued at $382,000 after purchasing an additional 4,729 shares during the last quarter. AQR Capital Management LLC boosted its stake in Supernus Pharmaceuticals by 35.2% during the 1st quarter. AQR Capital Management LLC now owns 85,224 shares of the specialty pharmaceutical company’s stock valued at $2,791,000 after purchasing an additional 22,182 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Supernus Pharmaceuticals by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,860 shares of the specialty pharmaceutical company’s stock valued at $978,000 after purchasing an additional 1,297 shares during the last quarter. Millennium Management LLC boosted its stake in Supernus Pharmaceuticals by 370.5% during the 1st quarter. Millennium Management LLC now owns 143,356 shares of the specialty pharmaceutical company’s stock valued at $4,695,000 after purchasing an additional 112,886 shares during the last quarter. Finally, Empowered Funds LLC boosted its stake in Supernus Pharmaceuticals by 16.0% during the 1st quarter. Empowered Funds LLC now owns 48,045 shares of the specialty pharmaceutical company’s stock valued at $1,573,000 after purchasing an additional 6,619 shares during the last quarter.

Insider Buying and Selling

In related news, Director Frederick M. Hudson sold 5,369 shares of the firm’s stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $50.61, for a total value of $271,725.09. Following the transaction, the director directly owned 60,413 shares of the company’s stock, valued at approximately $3,057,501.93. This trade represents a 8.16% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Padmanabh P. Bhatt sold 50,000 shares of the firm’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $50.28, for a total value of $2,514,000.00. Following the completion of the transaction, the vice president directly owned 17,044 shares in the company, valued at approximately $856,972.32. This represents a 74.58% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 116,406 shares of company stock valued at $5,911,086 in the last 90 days. 8.80% of the stock is owned by company insiders.

Supernus Pharmaceuticals Stock Performance

Shares of Supernus Pharmaceuticals stock opened at $48.21 on Monday. Supernus Pharmaceuticals, Inc. has a one year low of $30.83 and a one year high of $59.68. The stock’s fifty day moving average is $49.99 and its 200 day moving average is $49.64. The stock has a market cap of $2.80 billion, a P/E ratio of -94.53, a P/E/G ratio of 1.04 and a beta of 0.57.

Analysts Set New Price Targets

Several analysts have commented on SUPN shares. Zacks Research upgraded Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Wall Street Zen cut Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday. Craig Hallum set a $65.00 price target on Supernus Pharmaceuticals in a report on Wednesday, February 25th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Friday, March 27th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $62.17.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.